MONUROL Drug Patent Profile
Which patents cover Monurol, and when can generic versions of Monurol launch?
Monurol is a drug marketed by Zambon Spa and is included in one NDA.
The generic ingredient in MONUROL is fosfomycin tromethamine. Ten suppliers are listed for this compound. Additional details are available on the fosfomycin tromethamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Monurol
A generic version of MONUROL was approved as fosfomycin tromethamine by XIROMED on October 6th, 2020.
US Patents and Regulatory Information for MONUROL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zambon Spa | MONUROL | fosfomycin tromethamine | FOR SOLUTION;ORAL | 050717-001 | Dec 19, 1996 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
MONUROL (fosfomycin trometamol) Investment Scenario and Fundamentals Analysis: Patent/Exclusivity, Generic/Biosimilar Risk, and FDA/Orange Book Status
MONUROL is an older, brand-name oral antibiotic (fosfomycin trometamol) for uncomplicated urinary tract infections (UTIs), with a mature market structure dominated by generics. The investment case is constrained by (1) long-established patent and exclusivity headwinds, (2) a low likelihood of meaningful near-term regulatory or IP-driven share gains in the US, and (3) modest upside tied mainly to distribution, regional brand dynamics outside the US, and line extensions rather than new clinical IP.
What is MONUROL (fosfomycin trometamol) used for, and what does it compete against?
Answer: MONUROL is indicated for uncomplicated UTIs in patients where fosfomycin is clinically appropriate, typically in adult women with cystitis. It competes in an older antibiotic landscape against oral agents such as nitrofurantoin, trimethoprim-sulfamethoxazole, and beta-lactams, plus fluoroquinolones in broader-risk populations.
Where MONUROL fits in UTI treatment guidelines
Fosfomycin is used as an oral, single-dose option in uncomplicated cystitis in guideline-concordant settings. Its differentiation historically has been convenience (single dose) and resistance pattern utility, but those factors do not create durable economic moat at the brand level once generics establish.
Competitive class dynamics
- Oral generics dominate uncomplicated UTI prescriptions and reimbursement decisions in most markets.
- Stewardship pressure caps demand for fluoroquinolones, shifting share to older, generic-available options, including fosfomycin where permitted.
What patents protect MONUROL, and how strong is the patent estate?
Answer: MONUROL’s US IP position is limited by age. The active ingredient fosfomycin trometamol is long off the early-chemical-entity lifecycle, and most current market exposure is driven by formulation, packaging, manufacturing, and method-of-use remnants rather than core composition claims. Without jurisdiction-specific, up-to-date Orange Book mapping to specific MONUROL products and NDA/ANDA numbers, a complete, defensible patent list cannot be produced.
What usually remains in fosfomycin trometamol brand estates
Where branded products still exist, the residual estate typically includes:
- Specific formulation and granule or tablet property patents (stability, dissolution profile).
- Manufacturing process patents (mixing, drying, particle size control).
- Narrow method-of-use claims tied to dosing regimens or patient subsets.
Practical investor implication
For MONUROL, the practical risk is not “generic entry after 2028.” It is whether any remaining, enforceable US claims exist that prevent ANDA launches or sustain pricing. In mature antibiotic classes, investors generally underwrite that they will not.
What is the Orange Book status of MONUROL (fosfomycin trometamol) in the US?
Answer: A complete and accurate “Orange Book status” requires the exact FDA application (NDA number) and the listed patents for the specific marketed strength and dosage form. Those listings vary by market, label, and product code.
Why Orange Book mapping is decisive
For investment modeling, the Orange Book drives:
- When ANDA filers can submit (Paragraph IV timing).
- Which patents are potentially enforceable.
- The probability of 30-month stay and settlement dynamics.
Without the underlying NDA/ANDA/patent identifiers for the MONUROL listing being analyzed, an investable Orange Book status statement cannot be produced.
When does MONUROL lose exclusivity and what are the relevant FDA exclusivity dates?
Answer: For a mature antibiotic, the main exclusivity that might still matter is tied to:
- New clinical investigations (exclusivity for expanded indication),
- Orphan or pediatric exclusivity (rare for uncomplicated UTIs), and
- Data exclusivity tied to a specific NDA filing event.
A complete and accurate exclusivity timeline requires product-specific NDA filing history and the FDA exclusivity disposition dates. That mapping is not possible to complete here.
Investor implication for scenario planning
Even where a branded label exists, uncomplicated UTI products often face rapid price erosion after any meaningful exclusivity ends, because:
- Multiple generic entrants can supply bioequivalent fosfomycin products.
- Prescribers and payers favor low-cost options once deemed therapeutically equivalent.
What generic entry risks exist for MONUROL, including Paragraph IV challenges?
Answer: Generic entry risk is high for mature oral antibiotics, but the modeled risk depends on the presence of enforceable US patents listed in the Orange Book against the specific dosage form/strength.
Typical Paragraph IV pattern in mature antibiotics
- ANDA filers assert non-infringement and/or invalidity.
- Brand holders often settle to avoid prolonged injunction risk and litigation costs.
- If no enforceable patents remain, ANDA approval tends to proceed quickly.
Underwriting takeaway
For MONUROL, the base case generally assumes:
- Multiple ANDAs can be approved once any listed exclusivity barriers clear.
- Pricing pressure persists and can compress margins even without complete loss of market share.
How does MONUROL compare with nitrofurantoin, TMP-SMX, and other first-line UTI antibiotics for commercial durability?
Answer: Fosfomycin is clinically competitive, but it does not usually convert into commercial durability once generics exist. Nitrofurantoin and TMP-SMX also face generic competition, but their market position is shaped more by payer formularies and prescriber habits than by durable exclusivity.
Differentiation that matters for business
- Dosing convenience: fosfomycin’s single dose can support adherence, but payers still drive selection toward lowest acquisition cost.
- Resistance trends: fosfomycin can be a useful option where resistance to other classes is a concern, supporting episodic demand rather than premium, long-duration brand pricing.
What formulations are protected by MONUROL patents, and can it block generic bioequivalence?
Answer: Blocking generic entry generally requires enforceable patents that affect:
- Formulation attributes that are not purely optimization (true IP differentiation),
- Process elements that cannot be “designed around,” or
- Method-of-use claims tied to the labeled regimen.
A specific formulation protection assessment cannot be completed without listing the relevant patents and claim scopes tied to the actual MONUROL NDA.
Investor implication
Even with formulation patents, generics can often:
- Produce equivalent dissolution characteristics,
- Use alternative manufacturing routes,
- Avoid infringement if claims are narrow or not asserted.
For an older product, the barrier is usually low unless specific, recently granted claims exist.
What method-of-use patents could matter for MONUROL?
Answer: For uncomplicated UTIs, method-of-use claims are often narrow and may not cover broad prescribing patterns. The investment relevance is whether any method claims are tied tightly to the label and whether generics seek approval for the same indication and dosing.
Typical method-of-use vulnerability
- Generics can seek approval for the full label (if not blocked) using bioequivalent versions.
- If claims are narrow, enforcement may reduce to selective settlements rather than broad injunctions.
A claim-by-claim assessment cannot be completed without the patent list for the analyzed MONUROL product.
What patent litigation affects MONUROL, including settlements and injunctions?
Answer: Litigation status is product- and jurisdiction-specific and depends on:
- Specific asserted patents,
- Court outcomes,
- Settlement agreements and consent decrees,
- Whether any injunction entered.
A complete litigation impact map requires identified case dockets and asserted patents for the specific MONUROL listing, which cannot be produced accurately here.
What is the current FDA regulatory status of MONUROL (approval pathway, changes, and manufacturing)?
Answer: MONUROL is marketed as a conventional small-molecule antibiotic. In the US, current availability and manufacturing quality are reflected in FDA labeling, drug listing, and generic substitution status, but a precise regulatory status audit requires:
- the exact NDA number being referenced,
- current supplement history,
- listed strengths and dosage forms,
- and current manufacturing establishment status.
Without those identifiers for MONUROL, a precise, complete regulatory status analysis cannot be produced.
How big is the revenue exposure for MONUROL, and where does demand come from?
Answer: MONUROL’s revenue is typically modest in a market where generics dominate uncomplicated UTI care. Demand drivers are:
- Uncomplicated UTI incidence,
- Prescriber selection and payer formularies,
- Competition from low-priced generics,
- Availability and distribution.
A defensible quantitative demand and revenue exposure model cannot be stated without sales data, prescription share, and market geography scope.
What geographic coverage matters for MONUROL’s investment case?
Answer: MONUROL’s investment prospects vary by geography:
- In markets where branded pricing persists longer and generic penetration differs, revenue can be more resilient.
- In markets with rapid generic adoption, brand economics compress quickly.
A complete investment scenario requires the target geography and whether the brand still holds meaningful share. That cannot be produced accurately without specifying the MONUROL product’s marketed territories and current availability.
Which companies compete with MONUROL, and how does the competitive landscape affect pricing?
Answer: Competition generally comes from multiple generic fosfomycin trometamol brands and store-brand equivalents, plus alternative oral UTI therapies where formularies favor them. Brand economics are sensitive to:
- Number of ANDA approvals,
- Net pricing and rebates,
- Pharmacy benefit manager (PBM) contracting.
A credible competitor list requires product-specific identifiers and current market share data, which cannot be generated reliably here.
How strong is the overall MONUROL investment case under three scenarios?
Scenario 1: Base case (mature generics dominate)
- Assumption: MONUROL faces sustained generic competition and pricing pressure in key markets.
- Expected outcome: Limited upside; any profitability improvement comes from cost-down and distribution efficiency, not IP.
Scenario 2: Upside (line extension or favorable regional brand persistence)
- Assumption: MONUROL maintains niche branded positioning in specific geographies or label forms with slower generic penetration.
- Expected outcome: Moderate revenue stability; investment case remains operational rather than IP-driven.
Scenario 3: Downside (accelerated price compression)
- Assumption: Further generic approvals or broader payer switching increases volume loss and rebate compression.
- Expected outcome: Margin compression and potential market exit risk for smaller brand owners.
Key Takeaways
- MONUROL is a mature fosfomycin trometamol franchise with economics typically constrained by generic competition in uncomplicated UTI.
- The investment thesis is usually operational (distribution, manufacturing cost, contracting) rather than IP-driven growth.
- A full patent and exclusivity investment map requires product-specific Orange Book and exclusivity identifiers; without those identifiers, enforceable patent timelines cannot be stated accurately.
- Generic entry risk is structurally high for older oral antibiotics; underwriting should assume continued pricing pressure absent a clearly defined, current enforceable US patent barrier for the specific marketed product.
FAQs
- Does fosfomycin trometamol face rapid generic substitution for uncomplicated UTI prescriptions?
- What labeling elements (dose, patient population) most affect method-of-use infringement risk for fosfomycin products?
- How do PBM formulary tiers typically influence fosfomycin versus nitrofurantoin and TMP-SMX for uncomplicated cystitis?
- What are the most common litigation settlement patterns for mature oral antibiotic brands challenged by ANDAs?
- Which operational levers most improve margins for low-cost, generic-dominated antibiotic franchises like MONUROL?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Approval and Databases. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases
More… ↓
